XENE
Neutral signalScored 2026-10-27 Drivers: trend, fundamentals. Moteurs : tendance, fondamentaux.
Research, not advice.
À propos
Xenon Pharmaceuticals Inc.
- Nom
- Xenon Pharmaceuticals Inc.
- Secteur
- Healthcare
- Industrie
- Biotechnology
- Bourse
- NASDAQ
- Capitalisation
- $3.5B
- Employés
- 364
- PDG
- Ian C. Mortimer
- Site web
- https://www.xenon-pharma.com
- Marché
- ACADAVXLAXSMDNLIJAZZNBIX
Xenon Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company dedicated to discovering and advancing innovative treatments for individuals living with neurological disorders. The company operates primarily from its headquarters in Burnaby, Canada. Its robust clinical pipeline showcases several promising candidates: XEN496, an activator of Kv7 potassium channels, is currently in Phase III clinical trials for KCNQ2 developmental and epileptic encephalopathy. Another Kv7 potassium channel activator, XEN1101, is progressing through Phase II trials, targeting epilepsy and a range of other neurological conditions. The portfolio also includes NBI-921352, a selective inhibitor of the Nav1.6 sodium channel, which is undergoing Phase II clinical evaluation for SCN8A developmental and epileptic encephalopathy, alongside investigations for adult focal epilepsy and other potential indications. Furthermore, XEN007, a central nervous system-acting calcium channel modulator, is also in Phase II development. Beyond its internal development, Xenon Pharmaceuticals has established strategic collaborations. This includes a licensing and development agreement with Neurocrine Biosciences, Inc. focused on epilepsy treatments, and a partnership with Flexion Therapeutics, Inc. to advance PCRX301 (also known as XEN402), a Nav1.7 inhibitor, for post-operative pain management. Established in 1996, the company continues its mission to address significant unmet medical needs in neurology.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
ACHAT TOTAL: 45000 titres (~1681140 USD)
- Insiders
- Kelly Thomas PatrickMORTIMER IAN
- Total bought
-
$1,681,140
Avg buy (VWAP, 90d window) $37.36 vs last close $35.77 (-4.3%)
- Total sold
-
$683,234
Avg sell (VWAP, 90d window) $63.85 vs last close $35.77 (-44.0%)
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
$42,684 of that total is under a Rule 10b5-1 plan. It is shown here and left out of the score.
- Last activity
- 2026-09-30
- Liquidity
- Liquid $59,311,151/day · 20d vol
- Last synced
-
2026-10-27 06:47:12
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-09-30 | Kelly Thomas Patrick | Buy · P | 15,000 | $37.32 | $559,740 | Form 4 |
| 2026-09-30 | MORTIMER IAN | Buy · P | 30,000 | $37.38 | $1,121,400 | Form 4 |
| 2026-08-28 | KENNEY CHRISTOPHER JOHN | Sell · S · 10b5-1 | 700 | $60.98 | $42,684 | Form 4 |
| 2026-08-11 | GANNON STEVEN | Sell · S | 10,000 | $64.06 | $640,550 | Form 4 |
Sales marked 10b5-1 are scheduled in advance and don't count toward the Quorum score. Les ventes marquées 10b5-1 sont planifiées à l'avance et ne pèsent pas dans le score Quorum.
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Signal
Neutral signalScored 2026-10-27 Drivers: trend, fundamentals. Moteurs : tendance, fondamentaux.
XENE presents a deeply conflicted signal: insider cluster buying around the azetukalner NDA filing suggests some internal conviction, but the catalyst score of 25 with only 0.35 confidence reflects serious…
The first sentence of the analysis written for XENE on 2026-10-27 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Supports a bullish reading. Open-market purchases outweigh sales
- Narrative Pulls against a bullish reading. Stored narrative reading is in the bearish band
- Congress Unavailable or mixed. No purchase disclosures in the stored window
- Timing Pulls against a bullish reading. Close is more than 0.5 ATR under stored support
- Financial indicators Unavailable or mixed. Current ratio 13.42 · operating margin -4974% — readings disagree
Suggested stop 34.01, 1.5 ATR under the last close(4.9% under the last close). Reward/risk to the next stored resistance is 2.36. Research, not advice. Not an order.
Recent news
- 2026-10-20 Wolf Popper LLP Continues Investigation on Behalf of Xenon Pharmaceuticals Inc. Investors NEW YORK, Oct. 20, 2026 (GLOBE NEWSWIRE) -- Wolf Popper LLP is continuing its investigation into potential claims on behalf of purchasers of Xenon Pharmaceuticals Inc. (“Xenon”) common stock (NASDAQ: XENE).
- 2026-10-15 XENE''s Depression Trial Setback: Is Its Pipeline Still Attractive? Xenon pauses enrollment in late-stage depression trials after unexpected side effects, while its epilepsy pipeline offers growth potential.
- 2026-10-07 Wolf Popper LLP Continues Investigation on Behalf of Xenon Pharmaceuticals Inc. Investors NEW YORK, Oct. 07, 2026 (GLOBE NEWSWIRE) -- Wolf Popper LLP continues to investigate potential claims on behalf of purchasers of Xenon Pharmaceuticals Inc. (“Xenon”) common stock (NASDAQ: XENE).
- 2026-10-02 Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) VANCOUVER, BC and BOSTON, MA, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need, today announced equity inducement grants to eight new non-officer employees consisting of an aggregate of 17,850 share options and 10,500 restricted share units (RSUs). All of the foregoing share options and RSUs were approved by the Compensation Committee of the Company''s Board of Directors with an effective date of October 1, 2026 and were granted as inducements material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).
- 2026-09-29 Defence Therapeutics Appoints Finance Executive Sherry Aulin to Its Board of Directors Montreal, Quebec--(Newsfile Corp. - September 29, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC), ("Defence" or the "Company"), a publicly traded biotechnology company developing next-generation precision oncology therapeutics using its proprietary Accum® technology, is very pleased to announce the appointment of Sherry Aulin to its Board of Directors. Ms. Aulin will also serve as a member of the Company''s Audit Committee.
- 2026-09-27 Xenon Files Azetukalner NDA as It Pauses Psychiatry Trials for Tolerability Review Xenon Pharmaceuticals NASDAQ: XENE said it has filed its first new drug application for azetukalner as a treatment for focal-onset seizures, while pausing portions of its late-stage psychiatry program to evaluate changes intended to improve tolerability.
- 2026-09-23 XENE Investors Have Opportunity to Join Xenon Pharmaceuticals Inc. Fraud Investigation with SBS Law LOS ANGELES--(BUSINESS WIRE)---- $XENE--XENE Investors Have Opportunity to Join Xenon Pharmaceuticals Inc. Fraud Investigation with SBS Law.
- 2026-09-22 Xenon Pharmaceuticals Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Xenon Pharmaceuticals (XENE) Analysts cut price targets and reduced their estimates for azetukalner''s psychiatric commercial opportunity after Xenon Pharmaceuticals disclosed an enrollment pause in its Phase 3 depression trials -- XENE shares fell as much as 27.6%. NEW YORK, Sept.
- 2026-09-22 Xenon Pharmaceuticals: Azetukalner Still Has Potential As An Epilepsy Candidate Azetukalner''s focal-seizure application gives Xenon Pharmaceuticals Inc. a potential path to its first commercial revenues, subject to FDA approval. The psychiatry setback weakens expansion potential, but I think epilepsy still provides a viable foundation for the bull case. XENE''s liquid balance sheet should help it fund the remaining regulatory work and launch preparations.
- 2026-09-22 Wolf Popper LLP Announces Investigation on Behalf of Xenon Pharmaceuticals Inc. Investors NEW YORK, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Wolf Popper LLP is investigating potential claims on behalf of purchasers of Xenon Pharmaceuticals Inc. (“Xenon”) common stock (NASDAQ: XENE).
Market snapshot
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 66.1% | 0.0% | 0.0% | 100.0% | 100.0% | |
| Ebit Margin | -4598.6% | 0.0% | 0.0% | -1368.9% | -428.4% | |
| Ebitda Margin | -4564.7% | 0.0% | 0.0% | -1354.0% | -423.5% | |
| Operating Profit Margin | -4974.3% | 0.0% | 0.0% | -1368.9% | -428.4% | |
| Pretax Profit Margin | -4598.6% | 0.0% | 0.0% | -1327.7% | -427.9% | |
| Continuous Operations Profit Margin | -4612.1% | 0.0% | 0.0% | -1328.9% | -427.8% | |
| Net Profit Margin | -4612.1% | 0.0% | 0.0% | -1328.9% | -427.8% | |
| Bottom Line Profit Margin | -4612.1% | 0.0% | 0.0% | -1324.3% | -418.1% | |
| Current Ratio | 13.415 | 17.850 | 23.648 | 26.443 | 39.032 | |
| Quick Ratio | 13.415 | 17.850 | 23.648 | 26.443 | 39.032 | |
| Solvency Ratio | -0.859 | -5.361 | -4.850 | -3.797 | -3.549 | |
| Cash Ratio | 4.766 | 4.010 | 5.450 | 2.521 | 12.267 | |
| Price To Earnings Ratio | -10.280 | -13.023 | -16.872 | -19.141 | -17.650 | |
| Price To Earnings Growth Ratio | -0.229 | -1.270 | -0.519 | -1.168 | -0.156 | |
| Forward Price To Earnings Growth Ratio | -0.229 | -1.270 | -0.519 | -1.168 | -0.156 | |
| Price To Earnings Diluted Ratio | -10.280 | -13.023 | -16.872 | -19.141 | -17.650 | |
| Price To Earnings Diluted Growth Ratio | -0.229 | -1.270 | -0.519 | -1.168 | -0.156 | |
| Price To Book Ratio | 6.106 | 4.045 | 3.320 | 3.309 | 2.478 | |
| Price To Sales Ratio | 473.620 | 0.000 | 0.000 | 253.040 | 73.923 | |
| Price To Free Cash Flow Ratio | -12.690 | -16.553 | -20.411 | -23.560 | -19.048 | |
| Price To Operating Cash Flow Ratio | -12.726 | -16.834 | -21.200 | -24.253 | -19.610 | |
| Debt To Assets Ratio | 0.008 | 0.011 | 0.011 | 0.014 | 0.014 | |
| Debt To Equity Ratio | 0.014 | 0.012 | 0.012 | 0.014 | 0.015 | |
| Debt To Capital Ratio | 0.013 | 0.012 | 0.012 | 0.014 | 0.015 | |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Financial Leverage Ratio | 1.687 | 1.057 | 1.040 | 1.045 | 1.040 | |
| Working Capital Turnover Ratio | 0.013 | 0.000 | 0.000 | 0.017 | 0.052 | |
| Operating Cash Flow Ratio | -6.679 | -5.097 | -5.329 | -4.336 | -4.853 | |
| Operating Cash Flow Sales Ratio | -37.216 | 0.000 | 0.000 | -10.434 | -3.770 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.003 | 1.017 | 1.039 | 1.029 | 1.029 | |
| Debt Service Coverage Ratio | -224.130 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Interest Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Short Term Operating Cash Flow Coverage Ratio | -182.192 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Coverage Ratio | -35.136 | -20.121 | -13.329 | -9.433 | -8.417 | |
| Capital Expenditure Coverage Ratio | -349.334 | -58.988 | -25.873 | -34.012 | -33.903 | |
| Dividend Paid And Capex Coverage Ratio | -349.334 | -58.988 | -25.873 | -34.012 | -33.903 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -9.817 | -12.379 | -13.981 | -18.322 | -15.310 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 66.1% | ▲66.1% | ▲12.9% |
| Ebit Margin | -4598.6% | ▼-4598.6% | ▼-3319.4% |
| Ebitda Margin | -4564.7% | ▼-4564.7% | ▼-3296.2% |
| Operating Profit Margin | -4974.3% | ▼-4974.3% | ▼-3619.9% |
| Pretax Profit Margin | -4598.6% | ▼-4598.6% | ▼-3327.8% |
| Continuous Operations Profit Margin | -4612.1% | ▼-4612.1% | ▼-3338.3% |
| Net Profit Margin | -4612.1% | ▼-4612.1% | ▼-3338.3% |
| Bottom Line Profit Margin | -4612.1% | ▼-4612.1% | ▼-3341.2% |
| Current Ratio | 13.415 | ▼-4.434 | ▼-10.662 |
| Quick Ratio | 13.415 | ▼-4.434 | ▼-10.662 |
| Solvency Ratio | -0.859 | ▲4.502 | ▲2.824 |
| Cash Ratio | 4.766 | ▲0.756 | ▼-1.037 |
| Price To Earnings Ratio | -10.280 | ▲2.743 | ▲5.113 |
| Price To Earnings Growth Ratio | -0.229 | ▲1.041 | ▲0.439 |
| Forward Price To Earnings Growth Ratio | -0.229 | ▲1.041 | ▲0.439 |
| Price To Earnings Diluted Ratio | -10.280 | ▲2.743 | ▲5.113 |
| Price To Earnings Diluted Growth Ratio | -0.229 | ▲1.041 | ▲0.439 |
| Price To Book Ratio | 6.106 | ▲2.061 | ▲2.254 |
| Price To Sales Ratio | 473.620 | ▲473.620 | ▲313.504 |
| Price To Free Cash Flow Ratio | -12.690 | ▲3.863 | ▲5.762 |
| Price To Operating Cash Flow Ratio | -12.726 | ▲4.107 | ▲6.198 |
| Debt To Assets Ratio | 0.008 | ▼-0.003 | ▼-0.004 |
| Debt To Equity Ratio | 0.014 | ▲0.002 | ▲0.000 |
| Debt To Capital Ratio | 0.013 | ▲0.002 | ▲0.000 |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | 0.000 |
| Financial Leverage Ratio | 1.687 | ▲0.630 | ▲0.513 |
| Working Capital Turnover Ratio | 0.013 | ▲0.013 | ▼-0.003 |
| Operating Cash Flow Ratio | -6.679 | ▼-1.582 | ▼-1.420 |
| Operating Cash Flow Sales Ratio | -37.216 | ▼-37.216 | ▼-26.932 |
| Free Cash Flow Operating Cash Flow Ratio | 1.003 | ▼-0.014 | ▼-0.021 |
| Debt Service Coverage Ratio | -224.130 | ▼-224.130 | ▼-179.304 |
| Interest Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Short Term Operating Cash Flow Coverage Ratio | -182.192 | ▼-182.192 | ▼-145.754 |
| Operating Cash Flow Coverage Ratio | -35.136 | ▼-15.015 | ▼-17.849 |
| Capital Expenditure Coverage Ratio | -349.334 | ▼-290.346 | ▼-248.912 |
| Dividend Paid And Capex Coverage Ratio | -349.334 | ▼-290.346 | ▼-248.912 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -9.817 | ▲2.562 | ▲4.144 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $3.55B | $3.05B | $3.08B | $2.39B | $1.36B | |
| Enterprise value | $3.36B | $2.92B | $2.94B | $2.34B | $1.20B | |
| EV / Sales | 448.12x | 0.00x | 0.00x | 248.08x | 64.84x | |
| EV / Op. cash flow | -12.04x | -16.10x | -20.25x | -23.78x | -17.20x | |
| EV / Free cash flow | -12.01x | -15.83x | -19.50x | -23.10x | -16.71x | |
| EV / EBITDA | -9.82x | -12.38x | -13.98x | -18.32x | -15.31x | |
| Net debt / EBITDA | 0.56x | 0.57x | 0.65x | 0.37x | 2.14x | |
| Current ratio | 13.41x | 17.85x | 23.65x | 26.44x | 39.03x | |
| Income quality | 0.81x | 0.77x | 0.80x | 0.79x | 0.88x | |
| Graham net-net | $2 | $8 | $9 | $9 | $12 | |
| Tax burden | 100.3% | 98.3% | 99.8% | 100.1% | 100.0% | |
| Interest burden | 100.0% | 100.0% | 85.3% | 97.0% | 99.9% | |
| Working capital | $518.9M | $599.7M | $617.7M | $577.6M | $544.7M | |
| Invested capital | $534.2M | $617.9M | $636.5M | $594.5M | $557.2M | |
| Return on assets | -35.2% | -29.4% | -18.9% | -16.6% | -13.8% | |
| Operating ROA | -41.9% | -31.7% | -24.9% | -19.5% | -20.8% | |
| Return on tangible assets | -35.2% | -29.4% | -18.9% | -16.6% | -13.8% | |
| Return on equity | -59.5% | -31.0% | -19.7% | -17.4% | -14.3% | |
| Return on invested capital | -39.6% | -35.9% | -22.8% | -17.6% | -14.1% | |
| Return on capital employed | -39.7% | -36.6% | -22.8% | -17.7% | -14.2% | |
| Earnings yield | -9.7% | -7.7% | -5.9% | -5.3% | -5.8% | |
| Free cash flow yield | -7.9% | -6.0% | -4.9% | -4.2% | -5.2% | |
| Capex / Op. cash flow | -0.3% | -1.7% | -3.9% | -2.9% | -2.9% | |
| Capex / Depreciation | 31.4% | 120.1% | 158.6% | 206.0% | 226.3% | |
| Capex / Sales | 10.7% | 0.0% | 0.0% | 30.7% | 11.1% | |
| SG&A / Sales | 1061.8% | 0.0% | 0.0% | 347.8% | 119.1% | |
| R&D / Sales | 4012.5% | 0.0% | 0.0% | 1121.1% | 409.3% | |
| Stock comp / Sales | 716.1% | 0.0% | 0.0% | 216.0% | 54.3% | |
| Intangibles / Total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Days sales outstanding | 67d | 0d | 0d | 38d | 55d | |
| Days payables outstanding | 558d | 723d | 19d | 0d | 0d | |
| Operating cycle | 67d | 0d | 0d | 38d | 55d | |
| Cash conversion cycle | -491d | -723d | -19d | 38d | 55d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Change over 5 years